- Home
- ADPT vs PK Comparison
ADPT vs PK Comparison
Compare ADPT & PK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- PK
- Stock Information
- Founded
- ADPT 2009
- PK 1946
- Country
- ADPT United States
- PK United States
- Employees
- ADPT N/A
- PK N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- PK Real Estate Investment Trusts
- Sector
- ADPT Health Care
- PK Real Estate
- Exchange
- ADPT Nasdaq
- PK Nasdaq
- Market Cap
- ADPT 2.0B
- PK 2.1B
- IPO Year
- ADPT 2019
- PK N/A
- Fundamental
- Price
- ADPT $14.40
- PK $10.88
- Analyst Decision
- ADPT Strong Buy
- PK Hold
- Analyst Count
- ADPT 9
- PK 12
- Target Price
- ADPT $13.22
- PK $12.63
- AVG Volume (30 Days)
- ADPT 2.1M
- PK 3.2M
- Earning Date
- ADPT 11-06-2025
- PK 10-30-2025
- Dividend Yield
- ADPT N/A
- PK 12.95%
- EPS Growth
- ADPT N/A
- PK N/A
- EPS
- ADPT N/A
- PK 0.28
- Revenue
- ADPT $205,216,000.00
- PK $2,589,000,000.00
- Revenue This Year
- ADPT $32.76
- PK $0.65
- Revenue Next Year
- ADPT $15.81
- PK $2.28
- P/E Ratio
- ADPT N/A
- PK $38.80
- Revenue Growth
- ADPT 21.60
- PK N/A
- 52 Week Low
- ADPT $4.27
- PK $8.27
- 52 Week High
- ADPT $15.26
- PK $16.23
- Technical
- Relative Strength Index (RSI)
- ADPT 60.53
- PK 35.64
- Support Level
- ADPT $14.04
- PK $10.90
- Resistance Level
- ADPT $15.26
- PK $11.33
- Average True Range (ATR)
- ADPT 0.73
- PK 0.26
- MACD
- ADPT 0.05
- PK -0.12
- Stochastic Oscillator
- ADPT 69.09
- PK 1.95
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.